JAGX (Jaguar Health) Loans Receivable: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JAGX Jaguar Health Inc JAGX
38 GF Score
Price $0.93
GF Value $123.19
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Jaguar Health Loans Receivable?

Jaguar Health JAGX -2.20% 38 Loans Receivable is $0.00 Mil as of Jun. 2026. GuruFocus rates JAGX with a GF Score™ of 38/100 and a GF Value™ of $123.19 (Possible Value Trap). The stock has 3 warning signs investors should review.

Jaguar Health's Loans Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

Jaguar Health Loans Receivable Historical Data

* Premium members only.

The historical data trend for Jaguar Health's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jaguar Health Loans Receivable Chart

Jaguar Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Jaguar Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
JAGX
38GF Score
Jaguar Health Inc JAGX
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jaguar Health Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Jaguar Health (JAGX) has a Loans Receivable of $0.00 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Jaguar Health and its competitors.
Is Jaguar Health's Loans Receivable too high?
Jaguar Health's current Loans Receivable is $0.00 Mil. Overall, Jaguar Health has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Loans Receivable compare to TCRT and LABT?
Jaguar Health's Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Jaguar Health and its competitors. Jaguar Health's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Based on GuruFocus' analysis, Jaguar Health (JAGX) is currently considered Possible Value Trap. The stock's GF Value™ is $123.19, compared to a current price of $0.93 — trading 99.2% below its estimated fair value. The current Loans Receivable is $0.00 Mil. Jaguar Health's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Jaguar Health (JAGX), the current Loans Receivable is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jaguar Health (JAGX) Overvalued in 2026?

Based on GuruFocus' analysis, Jaguar Health stock appears to be undervalued. The current stock price of $0.93 is trading 99.2% below its estimated GF Value™ of $123.19. GuruFocus considers Jaguar Health to be Possible Value Trap.

Key valuation signals for JAGX:

  • Loans Receivable: $0.00 Mil
  • GF Value™: $123.19 vs. price of $0.93 (99.2% below fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the JAGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jaguar Health Business Description

Address 200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
38GF Score

Get the complete analysis for JAGX

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93
Price
$123.19
GF Value